AstraZeneca’s Imfinzi Wins Key EU Backing for First Perioperative Immunotherapy in Early Gastric Cancer
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AstraZeneca ( (GB:AZN) ) just unveiled an update.
AstraZeneca’s immunotherapy Imfinzi, in combination with standard FLOT chemotherapy, has received a positive opinion from the European Medicines Agency’s CHMP as a perioperative treatment for adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers. Based on Phase III MATTERHORN trial data, the regimen reduced the risk of disease progression, recurrence or death by 29% and the risk of death by 22% versus chemotherapy alone, with survival benefits consistent across PD-L1 status and no new safety signals, positioning Imfinzi to become the first immunotherapy-based perioperative standard of care in this setting in the EU and reinforcing AstraZeneca’s competitive foothold in early-stage oncology as regulators in other key markets review similar applications.
More about AstraZeneca
AstraZeneca is a global biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines, with a strong franchise in oncology. Its oncology portfolio includes targeted therapies and immunotherapies such as Imfinzi (durvalumab), aimed at treating a range of cancers across early and advanced disease stages in major markets including the US, Europe and Japan.
Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.
